glp 1 anesthesia How should we approach patients on #GLP1 agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the Guidelines and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like ColoWrap Blog | anesthesia

The takeaway is this: never assume you're covered or not covered until you've gone through the verification and prior authorization process

In some cases, you may not have significant pain or discomfort despite having a serious condition

Cardiovascular death: 2.5% (Wegovy) vs 3.0% (placebo) Heart failure composite: 3.4% vs 4.1% All-cause death: 4.3% vs 5.2% A related study determined that 100 people with obesity would need to be treated for three years to prevent one major cardiovascular event

GLP 1 analoglar etki mekanizmas , doal hormonun etkilerini taklit eder

For type 2 diabetes, NICE recommends GLP-1 agonists when other treatments haven't achieved target HbA1c levels, with specific consideration for cardiovascular and renal risk factors according to NICE guideline NG28